Key Takeaways RIGL's Tavalisse drove $68.5M sales in H1 2025, up 44$270-$280M on strong performance across its marketed products.FOLD's Galafold posted$233.1M H1 2025 sales, up 11% year over year, with patent protection to 2038.Both Rigel Pharmaceuticals (RIGL) and Amicus Therapeutics (FOLD) are developing and commercializing treatments for rare medical conditions where existing therapies are limited, with the goal of establi ...